Shots:
- Imcyse to receive up front, ~$180M as milestones along with royalties. Pfizer to purchase an equity stake in Imcyse
- Initially, the companies will collaborate to develop existing lead candidates and further optimize potential molecules. Later, Pfizer will lead clinical development and commercialization activities for the program
- The Imotope platform is a curative approach to severe autoimmune diseases. Imcyse plan to initiate a P-II study with its lead candidate in T1D and MS in 2022
Click here to read full press release/ article | Ref: Accesswire | Image: Imcyse
The post Pfizer Signs a License and Research Agreement with Imcyse to Develop Imotopes for Rheumatoid Arthritis first appeared on PharmaShots.
